Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Qin Song

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Ejhaem|February 23, 2023
Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group databaseXuan Zheng, Bao-Lin Qu, Xin Liu, et al.
American Journal of Hematology|May 26, 2020
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group studyShu-Nan Qi, Yong Yang, Yu-Jing Zhang, et al.
Haematologica|March 23, 2023
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG databaseXin Liu, Li-Ling Zhang, Bao-Lin Qu, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2025
Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group DatabaseKe Su, Xiao-Rong Hou, Qiu-Zi Zhong, et al.
Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.
Therapeutic Advances in Medical Oncology|October 14, 2024
Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphomaFei Luo, Qiu-Zi Zhong, Xin Liu, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
JCO Global Oncology|January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness AnalysisJing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Leukemia|August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Blood Advances|July 14, 2020
First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCGShu-Nan Qi, Yong Yang, Yu-Qin Song, et al.
Leukemia|September 18, 2020
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyYong Yang, Ying Wang, Xin Liu, et al.
Ejhaem|February 23, 2023
Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group databaseXuan Zheng, Bao-Lin Qu, Xin Liu, et al.
American Journal of Hematology|May 26, 2020
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group studyShu-Nan Qi, Yong Yang, Yu-Jing Zhang, et al.
Haematologica|March 23, 2023
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG databaseXin Liu, Li-Ling Zhang, Bao-Lin Qu, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2025
Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group DatabaseKe Su, Xiao-Rong Hou, Qiu-Zi Zhong, et al.
Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.
Therapeutic Advances in Medical Oncology|October 14, 2024
Optimizing the combination of chemotherapeutic drugs along with radiotherapy for extranodal NK/T-cell lymphomaFei Luo, Qiu-Zi Zhong, Xin Liu, et al.
Pageof 6